These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9296177)

  • 1. Serial MR in gene therapy for recurrent glioblastoma: initial experience and work in progress.
    Deliganis AV; Baxter AB; Berger MS; Marcus SG; Maravilla KR
    AJNR Am J Neuroradiol; 1997 Sep; 18(8):1401-6. PubMed ID: 9296177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma.
    Floeth FW; Aulich A; Langen KJ; Burger KJ; Bock WJ; Weber F
    AJNR Am J Neuroradiol; 2001 Sep; 22(8):1517-27. PubMed ID: 11559499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group.
    Shand N; Weber F; Mariani L; Bernstein M; Gianella-Borradori A; Long Z; Sorensen AG; Barbier N
    Hum Gene Ther; 1999 Sep; 10(14):2325-35. PubMed ID: 10515452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration.
    Packer RJ; Raffel C; Villablanca JG; Tonn JC; Burdach SE; Burger K; LaFond D; McComb JG; Cogen PH; Vezina G; Kapcala LP
    J Neurosurg; 2000 Feb; 92(2):249-54. PubMed ID: 10659011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial.
    Prados MD; McDermott M; Chang SM; Wilson CB; Fick J; Culver KW; Van Gilder J; Keles GE; Spence A; Berger M
    J Neurooncol; 2003 Dec; 65(3):269-78. PubMed ID: 14682377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy in brain tumours: implications of the size of glioblastoma on its curability.
    Izquierdo M; Cortés ML; Martín V; de Felipe P; Izquierdo JM; Pérez-Higueras A; Paz JF; Isla A; Blázquez MG
    Acta Neurochir Suppl; 1997; 68():111-7. PubMed ID: 9233425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial.
    Eck SL; Alavi JB; Alavi A; Davis A; Hackney D; Judy K; Mollman J; Phillips PC; Wheeldon EB; Wilson JM
    Hum Gene Ther; 1996 Aug; 7(12):1465-82. PubMed ID: 8844206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI characteristics and histological changes in glioblastoma after gene therapy.
    Weber FW; Floeth FW; Reifenberger G; Felsberg J; Aulich A; Kiwit JC; Bock WJ
    Front Radiat Ther Oncol; 1999; 33():244-52. PubMed ID: 10549494
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir.
    Smitt PS; Driesse M; Wolbers J; Kros M; Avezaat C
    Mol Ther; 2003 Jun; 7(6):851-8. PubMed ID: 12788659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MR of recurrent high-grade astrocytomas after intralesional immunotherapy.
    Smith MM; Thompson JE; Castillo M; Cush S; Mukherji SK; Miller CH; Quattrocchi KB
    AJNR Am J Neuroradiol; 1996; 17(6):1065-71. PubMed ID: 8791917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.
    Trask TW; Trask RP; Aguilar-Cordova E; Shine HD; Wyde PR; Goodman JC; Hamilton WJ; Rojas-Martinez A; Chen SH; Woo SL; Grossman RG
    Mol Ther; 2000 Feb; 1(2):195-203. PubMed ID: 10933931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme.
    Stenberg L; Englund E; Wirestam R; Siesjö P; Salford LG; Larsson EM
    Acta Radiol; 2006 Oct; 47(8):852-61. PubMed ID: 17050367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.
    Westphal M; Ylä-Herttuala S; Martin J; Warnke P; Menei P; Eckland D; Kinley J; Kay R; Ram Z;
    Lancet Oncol; 2013 Aug; 14(9):823-33. PubMed ID: 23850491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.
    Ji N; Weng D; Liu C; Gu Z; Chen S; Guo Y; Fan Z; Wang X; Chen J; Zhao Y; Zhou J; Wang J; Ma D; Li N
    Oncotarget; 2016 Jan; 7(4):4369-78. PubMed ID: 26716896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cure following gene therapy for recurrent glioblastoma multiforme?
    Karabatsou K; Bernstein M
    Acta Neurochir (Wien); 2008 Jun; 150(6):611-2. PubMed ID: 18511998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The biosafety of the HSV-TK/GCV gene therapy in five cases of recurrent glioblastoma multiforme].
    Adachi N; Könü DL; Frei K; Yonekawa Y
    No Shinkei Geka; 2000 Nov; 28(11):965-74. PubMed ID: 11127592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma.
    Klatzmann D; Valéry CA; Bensimon G; Marro B; Boyer O; Mokhtari K; Diquet B; Salzmann JL; Philippon J
    Hum Gene Ther; 1998 Nov; 9(17):2595-604. PubMed ID: 9853526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trial.
    Oraee-Yazdani S; Tavanaei R; Rostami F; Hajarizadeh A; Mehrabadi M; Akhlaghpasand M; Tamaddon M; Khannejad S; Yazdani KO; Zali A
    J Transl Med; 2023 May; 21(1):350. PubMed ID: 37245011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and neuroimaging findings in 12 cases of recurrent glioblastoma with communicating hydrocephalus.
    Onuma K; Ishikawa E; Matsuda M; Hirata K; Osuka S; Yamamoto T; Masumoto T; Zaboronok A; Matsumura A
    Neurol Med Chir (Tokyo); 2013; 53(7):474-81. PubMed ID: 23883558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.
    Rainov NG
    Hum Gene Ther; 2000 Nov; 11(17):2389-401. PubMed ID: 11096443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.